Abstract
Hypocretin neuropeptides have been shown to regulate transitions between wakefulness and sleep through stabilization of sleep promoting GABAergic and wake promoting cholinergic/monoaminergic neural pathways. Hypocretin also influences other physiologic processes such as metabolism, appetite, learning and memory, reward and addiction, and ventilatory drive. The discovery of hypocretin and its effect upon the sleep-wake cycle has led to the development of a new class of pharmacologic agents that antagonize the physiologic effects of hypocretin (i.e. hypocretin antagonists). Further investigation of these agents may lead to novel therapies for insomnia without the side-effect profile of currently available hypnotics (e.g. impaired cognition, confusional arousals, and motor balance difficulties). However, antagonizing a system that regulates the sleep-wake cycle while also influencing non-sleep physiologic processes may create an entirely different but equally concerning side-effect profile such as transient loss of muscle tone (i.e. cataplexy) and a dampened respiratory drive. In this review, we will discuss the discovery of hypocretin and its receptors, hypocretin and the sleep-wake cycle, hypocretin antagonists in the treatment of insomnia, and other implicated functions of the hypocretin system.
Keywords: Hypocretin, orexin, insomnia, narcolepsy, cataplexy, sleep, MK-4305, almorexant, magnocellular, appetite, amygdala, tuberomammillary, dynorphin, isoquinolin, histamine, hypercapnic, cognition, morphine
Current Pharmaceutical Design
Title: Hypocretin Antagonists in Insomnia Treatment and Beyond
Volume: 17 Issue: 15
Author(s): Chad Ruoff, Michelle Cao and Christian Guilleminault
Affiliation:
Keywords: Hypocretin, orexin, insomnia, narcolepsy, cataplexy, sleep, MK-4305, almorexant, magnocellular, appetite, amygdala, tuberomammillary, dynorphin, isoquinolin, histamine, hypercapnic, cognition, morphine
Abstract: Hypocretin neuropeptides have been shown to regulate transitions between wakefulness and sleep through stabilization of sleep promoting GABAergic and wake promoting cholinergic/monoaminergic neural pathways. Hypocretin also influences other physiologic processes such as metabolism, appetite, learning and memory, reward and addiction, and ventilatory drive. The discovery of hypocretin and its effect upon the sleep-wake cycle has led to the development of a new class of pharmacologic agents that antagonize the physiologic effects of hypocretin (i.e. hypocretin antagonists). Further investigation of these agents may lead to novel therapies for insomnia without the side-effect profile of currently available hypnotics (e.g. impaired cognition, confusional arousals, and motor balance difficulties). However, antagonizing a system that regulates the sleep-wake cycle while also influencing non-sleep physiologic processes may create an entirely different but equally concerning side-effect profile such as transient loss of muscle tone (i.e. cataplexy) and a dampened respiratory drive. In this review, we will discuss the discovery of hypocretin and its receptors, hypocretin and the sleep-wake cycle, hypocretin antagonists in the treatment of insomnia, and other implicated functions of the hypocretin system.
Export Options
About this article
Cite this article as:
Ruoff Chad, Cao Michelle and Guilleminault Christian, Hypocretin Antagonists in Insomnia Treatment and Beyond, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197089
DOI https://dx.doi.org/10.2174/138161211796197089 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Cardiovascular & Hematological Agents in Medicinal Chemistry Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Retinoid-Induced Limb Malformations
Current Pharmaceutical Design Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications
Current Topics in Medicinal Chemistry Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews The Echinocandins: Total and Semi-Synthetic Approaches in Antifungal Drug Discovery
Anti-Infective Agents in Medicinal Chemistry Treating Neonatal Brain Injury - Promise and Inherent Research Challenges
Recent Patents on Inflammation & Allergy Drug Discovery Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Progress on Hydroxyapatite-Based Dense Biomaterials for Load Bearing Bone Substitutes
Recent Patents on Materials Science Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K. Anagnostopoulou, D.P. Mikhailidis and G. Kolovou)]
Current Drug Targets